UNSPSC 51294905: Nuclotixene

This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6DTQ2MGV34. European Medicines Agency schedules Nuclotixene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09389MIG. Nuclotixene generally arises in the molecular formula C21H20CLNS.

UNSPSC 51294905 Nuclotixene, a Commodity code, represents pharmaceutical and medical products that state and local governments procure for public health and emergency response programs. Based on recent solicitation activity, the code captures naloxone and related drug-response systems distributed through community health initiatives, with procurement structured around competitive bidding for annual supply agreements. The issuing bodies under this code include county health departments and municipal public health agencies managing opioid-response and harm-reduction programs. Vendors must meet standard compliance requirements including E-Verify authorization, drug-free workplace certification, and appropriate insurance coverage (workers' compensation, commercial general liability, and professional liability).

Seminole County, Florida, posted the only recent documented opportunity under this code—IFB60459723LAS, a competitive bid for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The IFB closed on July 26, 2023, and carried a two-year initial term with one-year renewal option on a fixed-fee basis. The procurement noted potential FEMA funding with attendant federal compliance requirements. The limited recent activity under this specific code suggests either narrow applicability or that similar pharmaceutical procurements are tagged to broader medical-supply or health-services codes. Interested vendors should monitor Seminole County's e-Procurement Portal and similar county health department channels in Florida for future naloxone and drug-response equipment needs.